MED Stock Forecast 2025-2026
Distance to MED Price Targets
MED Price Momentum
🤔 Considering Medifast (MED)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest MED Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, MED has a neutral consensus with a median price target of $15.75 (ranging from $15.00 to $16.50). Currently trading at $13.94, the median forecast implies a 13.0% upside. This outlook is supported by 0 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Linda Bolton Weiser at DA Davidson, projecting a 18.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MED Analyst Ratings
MED Price Target Range
Latest MED Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MED.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 19, 2025 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $16.50 |
| Nov 5, 2024 | DA Davidson | Linda Bolton Weiser | Neutral | Upgrade | $17.00 |
| Jul 22, 2024 | DA Davidson | Linda Bolton Weiser | Underperform | Maintains | $17.50 |
| Jun 5, 2024 | DA Davidson | Linda Bolton Weiser | Underperform | Downgrade | $17.50 |
| Apr 30, 2024 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $25.00 |
| Feb 21, 2024 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $40.00 |
| Oct 13, 2023 | Stephens & Co. | Jim Salera | Equal-Weight | Initiates | $82.00 |
| Aug 8, 2023 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $80.00 |
| Jul 31, 2023 | DA Davidson | Neutral | Maintains | $0.00 | |
| May 2, 2023 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $71.00 |
| Feb 22, 2023 | DA Davidson | Linda Bolton Weiser | Neutral | Maintains | $94.00 |
| Nov 4, 2022 | DA Davidson | Linda Bolton Weiser | Neutral | Downgrade | $106.00 |
| Aug 4, 2022 | DA Davidson | Linda Bolton Weiser | Buy | Maintains | $278.00 |
| Aug 4, 2022 | Jefferies | Stephanie Wissink | Hold | Downgrade | $150.00 |
| Jun 2, 2022 | DA Davidson | Linda Bolton Weiser | Buy | Maintains | $352.00 |
| Feb 24, 2022 | DA Davidson | Linda Bolton Weiser | Buy | Maintains | $341.00 |
| Nov 8, 2021 | DA Davidson | Linda Bolton Weiser | Buy | Maintains | $349.00 |
| May 5, 2021 | DA Davidson | Linda Bolton Weiser | Buy | Maintains | $395.00 |
| Feb 26, 2021 | DA Davidson | Linda Bolton Weiser | Buy | Maintains | $302.00 |
| Jan 25, 2021 | Jefferies | Stephanie Wissink | Buy | Upgrade | $265.00 |
Medifast Inc. (MED) Competitors
The following stocks are similar to Medifast based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Medifast Inc. (MED) Financial Data
Medifast Inc. has a market capitalization of $152.47M with a P/E ratio of 73.4x. The company generates $602.46M in trailing twelve-month revenue with a 0.3% profit margin.
Revenue growth is -37.7% quarter-over-quarter, while maintaining an operating margin of +0.6% and return on equity of +1.0%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Medifast Inc. (MED) Business Model
About Medifast Inc.
Provides weight management and healthy living products.
Medifast operates a direct selling model primarily through its OPTAVIA Coaches, who offer personalized support and guidance to customers. The company generates revenue by selling a variety of meal replacement products, snacks, and hydration solutions tailored for individuals aiming for sustainable lifestyle changes.
Medifast differentiates itself by combining nutritional science with personalized coaching, catering to the increasing consumer interest in health and wellness. This innovative approach not only fosters community engagement but also positions the company favorably in the competitive health sector, ensuring its adaptability and relevance in the market.
Company Information
Sector
Consumer Cyclical
Industry
Personal Services
Employees
504
CEO
Mr. Daniel R. Chard
Country
United States
IPO Year
1993
Website
medifastinc.comMedifast Inc. (MED) Latest News & Analysis
Medifast, Inc. (NYSE:MED) will hold its Q4 2024 Earnings Conference Call on February 18, 2025, at 4:30 PM ET, featuring executives including CEO Dan Chard and CFO Jim Maloney.
The upcoming earnings call for Medifast will provide insights into financial performance and strategic direction, influencing investor sentiment and stock valuation.
Medifast (NYSE: MED) reported Q4 2024 revenue of $119.0 million, with 27,100 active OPTAVIA coaches. Net income was $0.8 million, with adjusted net income at $1.1 million.
Medifast's Q4 revenue and active coach metrics indicate potential growth or decline in its business model. Profitability and EPS figures affect stock valuation and investor sentiment.
Medifast (MED) reported Q3 earnings of $0.10 per share, surpassing the Zacks Consensus Estimate of a loss of $0.27. This is a decline from $1.09 per share a year earlier.
Medifast's earnings beat expectations, signaling potential recovery or improved performance, despite a significant decline from last year, which may impact investor sentiment and stock valuation.
Medifast's Q2 results indicate difficulties with customer acquisition, but the company plans to focus on improving coach productivity moving forward.
Weak customer acquisition may hinder Medifast's growth, impacting revenue. Focus on improving coach productivity could indicate efforts to boost sales and customer retention.
Medifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2024
1 month agoMedifast (NYSE: MED) will announce Q4 and full-year 2024 financial results on February 18, 2025, after market close, followed by a conference call with executives.
Medifast's upcoming financial results announcement is crucial for assessing its performance and potential growth, impacting stock valuation and investor sentiment.
Medifast is strategically focused on innovation and has a strong operational framework, positioning it for growth in the weight loss and GLP-1 medication markets.
Medifast's focus on innovation and strong operations positions it for growth in a lucrative market, potentially driving higher revenues and stock performance.
Frequently Asked Questions About MED Stock
What is Medifast Inc.'s (MED) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Medifast Inc. (MED) has a median price target of $15.75. The highest price target is $16.50 and the lowest is $15.00.
Is MED stock a good investment in 2025?
According to current analyst ratings, MED has 0 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $13.94. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MED stock?
Wall Street analysts predict MED stock could reach $15.75 in the next 12 months. This represents a 13.0% increase from the current price of $13.94. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Medifast Inc.'s business model?
Medifast operates a direct selling model primarily through its OPTAVIA Coaches, who offer personalized support and guidance to customers. The company generates revenue by selling a variety of meal replacement products, snacks, and hydration solutions tailored for individuals aiming for sustainable lifestyle changes.
What is the highest forecasted price for MED Medifast Inc.?
The highest price target for MED is $16.50 from Linda Bolton Weiser at DA Davidson, which represents a 18.4% increase from the current price of $13.94.
What is the lowest forecasted price for MED Medifast Inc.?
The lowest price target for MED is $15.00 from at , which represents a 7.6% increase from the current price of $13.94.
What is the overall MED consensus from analysts for Medifast Inc.?
The overall analyst consensus for MED is neutral. Out of 4 Wall Street analysts, 0 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $15.75.
How accurate are MED stock price projections?
Stock price projections, including those for Medifast Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
